{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-025661","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2022-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.208375+00:00","generated_at":"2026-06-27T05:59:46.264277+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Protagonist Therapeutics increases inducement plan share reserve by 500,000 shares","bullets":["Compensation Committee approved amendment to 2018 Inducement Plan on Feb 15, 2022, adding 500,000 shares (total 1,750,000).","New shares reserved exclusively for inducement grants to new employees not previously employed by the company.","Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4) for inducement awards."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-025661","json":"https://secwatch.observer/filing/0001104659-22-025661.json","markdown":"https://secwatch.observer/filing/0001104659-22-025661.md","text":"https://secwatch.observer/filing/0001104659-22-025661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922025661/0001104659-22-025661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922025661/tm227311d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:59:46.264277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}